291 related articles for article (PubMed ID: 16539821)
1. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
4. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
5. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with rituximab of autoimmune disease: results from AADEA's registry].
Callejas Rubio JL; Camps MT; García-Hernández F;
Med Clin (Barc); 2008 Jan; 130(2):79. PubMed ID: 18221681
[No Abstract] [Full Text] [Related]
7. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
9. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
10. A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
Park CY; Chung CH
J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698
[TBL] [Abstract][Full Text] [Related]
11. Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.
So MW; Koo BS; Kim YJ; Kim YG; Lee CK; Yoo B
Mod Rheumatol; 2014 Sep; 24(5):855-7. PubMed ID: 24517558
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion in autoimmune disease.
Gorman C; Leandro M; Isenberg D
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus].
Lehembre S; Macario-Barrel A; Musette P; Carvalho P; Joly P
Ann Dermatol Venereol; 2006 Jan; 133(1):53-5. PubMed ID: 16495854
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab for treatment of patients with systemic autoimmune diseases].
García Hernández FJ; Ocaña Medina C; González León R; Garrido Rasco R; Colorado Bonilla R; Castillo Palma MJ; Sánchez Román J
Med Clin (Barc); 2007 Mar; 128(12):458-62. PubMed ID: 17408540
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
Silverman GJ
Front Biosci; 2007 Jan; 12():2194-206. PubMed ID: 17127456
[TBL] [Abstract][Full Text] [Related]
18. [The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia].
Martínez Velasco E; Gómez Castillo JJ; Fernández Megía MJ; González Joga B; Barreda Hernández D; Gómez Roncero MI
Farm Hosp; 2007; 31(2):124-7. PubMed ID: 17590122
[TBL] [Abstract][Full Text] [Related]
19. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
20. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]